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Abstract
Background We provide population-based long-term survival indicators of breast cancer patients by quantifying the observed 
survival, and the probabilities of death due to breast cancer and to other causes by age and tumor stage at diagnosis.
Methods We included a total of 10,195 female patients diagnosed before 85 years with invasive primary breast cancer in 
Girona and Tarragona during the periods 1985–1994 and 1995–2004 and followed-up until December 31st 2014. The survival 
indicators were estimated at 5, 10, 15 and 20 years of follow-up comparing diagnostic periods.
Results Comparing diagnostic periods: I) the probability of death due to other causes did not change; II) the 20-year sur-
vival for women diagnosed ≤ 49 years increased 13% (1995–2004 = 68%; 1985–1994:55%), whereas their probability of 
death due to breast cancer decreased at the same pace (1995–2004 = 29%; 1985–1994 = 42%); III) at 10 years of follow-up, 
decreases in the probabilities of death due to breast cancer across age groups switched from 11 to 17% resulting in a risk of 
death reduction of 19% after adjusting by stage. During 1995–2004, the stage-specific 10-year probabilities of death due to 
breast cancer switched from: 3–6% in stage I, 18–20% in stage II, 34–46% in stage III and surpassed 70% in stage IV beyond 
5 years after diagnosis.
Conclusions In our study, women diagnosed with breast cancer had higher long-term probability to die from breast cancer 
than from other causes. The improvements in treatment and the lead-time bias in detecting cancer in an early stage resulted 
in a reduction of 19% in the risk of death between diagnostic periods.
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Abbreviations
BC  Breast cancer
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PBC  Probability of death due to BC
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Introduction
Breast cancer (BC) is the most frequent tumor and the first 
cause of cancer death among European women in the recent 
years [1]. In Spain, it has been estimated that 28,000 new 
BC cases were diagnosed in 2015, with an incidence rate 
(adjusted for the European population) of 88.3 cases per 
100,000 women-years, that leads to an intermediate posi-
tion in Europe [2]. It is estimated that 1 in 9 Spanish women 
will develop BC throughout their life [3], with a mean age 
at diagnosis of 60 years, although BC incidence rates have 
shown a downturn since 2001 among Spanish women over 
45 [4].
Improvements in 5-year BC survival have been observed 
[5–8] in parallel with a decline in the risk of BC mortality 
specially marked in women under 50 years of age [9]. Since 
life expectancy can lengthen by several decades in young 
BC patients [10], to provide long-term survival estimates 
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is called for. To our knowledge, population-based survival 
studies in Spain have been provided up to 5-year survival 
estimates [5–7, 11], but not beyond this follow-up. It is of 
crucial interest the assessment of the most recent survival 
estimates, since several international studies have suggested 
a non-decreasing excess mortality beyond 10 years after BC 
diagnosis [12–18].
In a previous study, we provided long-term estimates of 
the survival probabilities of BC patients diagnosed before 
50 years by stage and period of diagnosis using a small 
cohort (N = 998) from the population-based cancer registry 
of Girona [7]. In the present study, we provide survival indi-
cators of BC patients based on a larger cohort of N = 10,195 
women from two population-based cancer registries, Girona 
and Tarragona, taking into account the age and BC stage 
and period of diagnosis. Our aim is in quantifying the con-
tribution of BC to overall mortality, assessing the long-term 
crude probabilities of death, by age and stage, due to BC 
and other causes among patients diagnosed before 84 years.
Materials and methods
Data
BC data was obtained from the population-based cancer 
registries of Girona and Tarragona, which cover a popula-
tion of 771,854 women (2011 Catalonia census) [19]. Each 
woman with BC in these provinces has been followed-up to 
December 31st, 2014. In addition to the active and passive 
follow-up via hospitals, two passive follow-ups were per-
formed using record linkage: one linking BC data with the 
Catalonian Mortality Registry (which covers the four Cata-
lan provinces, Girona, Tarragona, Lleida and Barcelona) and 
another linking data with the National Death Index of the 
Spanish Ministry of Health. The patients not found to be 
dead at the end of follow-up were considered as censored.
We included a total of N = 10,195 female patients aged 
15–84 years and diagnosed with invasive primary BC (codes 
174 and C50 of the 9th and 10th editions of the Interna-
tional Classification of Diseases, ICD-9 and ICD-10, respec-
tively) during the time periods 1985–1994 (N = 4211) and 
1995–2004 (N = 5984). From these, data on the stage at 
diagnosis was extracted through medical records review. 
Variables considered for the analysis were age, partitioned 
into ≤ 49, (49–59), (59–74) and (74–84), and stage at diag-
nosis. Stage classification was based on the TNM classi-
fication system unified to the 5th edition of the American 
Joint Committee on cancer staging manual [20] to compare 
the survival indicators by stage between 1985–1994 and 
1995–2004. Patients were classified as stage I, II, III and IV 
when staging was available at the moment of diagnosis, and 
missing stage otherwise.
Statistical analyses
We calculated the observed survival (OS), and the prob-
abilities of death due to BC (PBC) and other causes (POC) 
by age and stage at diagnosis at 5, 10, 15 and 20 years of fol-
low-up and we compared these three probabilities between 
time periods at diagnosis 1985–1994 and 1995–2004 and 
across age groups. Since life expectancy among Catalan 
women is 90 years [19], we did not estimate these probabili-
ties beyond 5 years of follow-up for patients aged between 
74 and 84 years at diagnosis. In the same line, we did not 
estimate these probabilities beyond 15 years of follow-up for 
patients aged between 59 and 74 years at diagnosis.
In brief, up to year T, P(t ≤ T) is the cumulative probabil-
ity to die from any cause in the cohort, whereas OS(T > t) is 
the cumulative probability to survive in the cohort beyond 
the year T, where OS(T > t) + P(t ≤ T) = 1. The P(t ≤ T) can 
be estimated as a sum of two probabilities: PBC(t ≤ T) is the 
estimated cumulative probability to die due to the disease 
under study, BC in our case, and POC(t ≤ T), the estimated 
cumulative probability to die due to causes other than the 
cancer of interest [21]. These probabilities can be estimated 
making use of the excess hazard of death [22, 23] under a 
competing risk’s approach to survival, as described in a pre-
vious study [7]. This approach allows providing estimates of 
PBC and POC without knowing the exact cause of death [7, 
22, 23], where it is only needed to know if the patient dies 
or not because of any cause at the end of study. Therefore, 
since OS(t > T) + PBC(t ≤ T) + POC(t ≤ T) = 1, we will 
present these probabilities depicted in a survival graph in 
the results section. We derived their corresponding 2.5, and 
97.5% percentiles using the R-library relsurv [23].
Since the closing date of follow-up was December  31st, 
2014, for patients diagnosed during 1995–2004, we esti-
mated the probabilities of interest beyond 10 years of fol-
low-up using different cohorts, as performed in the previ-
ous study [7]. Therefore, 11-year follow-up was estimated 
using the patients diagnosed during the period 1995–2003, 
whereas 12-year follow-up was estimated using the 
patients diagnosed during the period 1995–2002 and so on 
up to 19 years. We used the cohort of patients diagnosed in 
1994 to estimate these probabilities at 20-year follow-up.
First we assessed up to 20-year survival estimates 
between periods of diagnosis across age groups. Second, we 
compared 10-year OS between 1985–1994 and 1995–2004 
across stage and age groups. A Cox proportional hazards 
model was used to assess hazard ratios of all-cause mortality 
by age, stage and period of diagnosis. Finally, since stage 
information was available in 86.2% of the patients diagnosed 
during 1995–2004, 10-year estimates of the probabilities of 
interest provide the most recent long-term survival indica-
tors by age and stage in Girona and Tarragona.
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The Supplementary material file presents additional 
tables, figures and an extension of the statistical methods.
Results
Comparison of long‑term survival between 1985–
1994 and 1995–2004 by age groups
Comparing the time periods 1985–1994 and 1995–2004, 
there were no significant differences in the age distribu-
tion of the patients considered in the cancer registries, see 
Table 1. Table S1 in the supplementary material presents 
survival indicators and crude probabilities of death by period 
of diagnosis across specific age groups. Figure 1 depicts the 
PBC, POC and the OS comparing survival indicators by 
period of diagnosis in women ≤ 49 and > 49. This figure 
shows the improvement in OS in parallel with the reduction 
in the PBC, whereas POC did not change between diagnostic 
periods. Worth noting is that, among women ≤ 49, 20-year 
OS for women was 55% (PBC = 42%) if they were diag-
nosed during 1985–1994, whereas based on our estimations, 
it could reach 68% (PBC = 29%) if they were diagnosed 
during 1995–2004.
Comparing 10-year probabilities of death due to BC and 
OC by period of diagnosis and age group (Fig. 2), differences 
in the PBC between 1985–1994 and 1995–2004 were 11% 
among women ≤ 49 (1985–1994: 33%;1995–2004: 22%), 
17% among women (50–59) (1985–1994: 37%; 1995–2004: 
20%), and 14% among women (60–74) (1985–1994: 37%; 
1995–2004:23%), and 10% among women aged (74–84). 
PBC surpassed POC in all age groups except in the old-
est age group, where confidence intervals of POC overlap 
those of PBC beyond 5 years of follow-up. Beyond 10 years 
of follow-up (Table S1), the largest differences in PBC 
between periods could have reached 12% among women 
aged (59–74) at 15 years (PBC 41% in 1985–1994; 29% 
in 1995–2004) and 20% among women aged (49–59) at 
20 years (48% in 1985–1994; 28% in 1995–2004). Differ-
ences in the OS between diagnostic periods are similar to 
those found in the PBC.
Comparison of observed survival by age–stage 
between diagnostic periods
Table 2 presents the stage distribution across age groups 
by period of diagnosis. Stage was available in 20.6% 
(N = 867) of the patients diagnosed during the period 
1985–1994 and in 86.2% (N = 5160) in those patients 
diagnosed during 1995–2004. Among patients with stag-
ing information in 1985–1994, there was a higher percent-
age of patients diagnosed in Stage I during 1995–2004 
(34.6%) than during 1985–1994 (26.5%) and a higher 
percentage of patients diagnosed in stage IV (13.3 vs 
6.8%) than during 1995–2004 (6.8%). Differences in the 
mean age at diagnosis were also assessed and not found 
to be statistically significant. We also compared 10-year 
OS between time periods across stages: I) hazard rates in 
periods 1985–1994 and 1995–2004 were of similar magni-
tude by age and stage (Table 3), but showing that patients 
diagnosed during 1995–2004 had 19% reduction in risk of 
death compared to those diagnosed in 1985–2004; II) we 
found significant differences in survival between periods in 
stage I patients (Supplementary material: Figure S1 Wil-
coxon test p < 0.001; Table S2 10-year OS in 1985–1994: 
85%; 1995–2004: 89%) and in stage IV (Wilcoxon test 
p < 0.05; 10-year OS in 1985–1994: 2%; 1995–2004: 7%).
Age‑stage observed survival and crude probabilities 
of death for patients diagnosed during 1995–2004
Table 4 presents the 5-year and 10-year OS and the crude 
probabilities of death for the cohort of patients diagnosed 
during 1995–2004 by age and stage at diagnosis. Differ-
ences in 5-year OS switched from 7 to 11% comparing 
stages I and II, and from 13 to 22% comparing stages II 
and III. We note that the PBC switched from 1 to 3% in 
stage I, from 9 to 12% in stage II and from 23 to 34% 
in stage III. The PBC in stage IV patients was estimated 
to surpass 70% in all age groups, since these patients 
showed that less than 29% and less than 20% could sur-
vive more than 5 years among those diagnosed ≤ 49 years 
and beyond 49 years, respectively. These figures must be 
interpreted with caution due to the small sample size (less 
than 30 patients at risk).
Similar gradient of differences was found in 10-year 
OS: 13–18% comparing stages I and II, and 14–23% com-
paring stages II and III. The 10-year PBC in 1995–2004 
switched from 3% (ages (49–59]) to 6% (≤ 49) in stage 
I, 18% (49–59) to 20% in stage II and from 34% (≤ 49) 
to 46% (59–74) in stage III. In stage IV patients, PBC 
surpassed 88% in all age groups and a very small sample 
size (less than 10 patients) could reach 10-year follow-up.
Table 1  Age-group distribution of the breast cancer patients included 
in the study during the time periods 1985–1994 and 1995–2004
Age 1985–1994 1995–2004
N (%) N (%)
0–49 1110 26.4 1561 26.1
50–59 844 20.0 1307 21.8
60–74 1564 37.1 2074 34.7
75–84 693 16.5 1042 17.4
TOTAL 4211 100 5984 100
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Discussion
We have estimated that risk of death among BC 
patients was reduced by 19% in 1995–2004 compared 
to 1985–1994 and the improvement in 10-year survival 
between the two periods of diagnosis was mainly due to 
the decrease in the PBC, since the POC did not change 
between these time periods. We have estimated that the 
difference in the PBC between diagnostic periods may 
continue or even increase beyond 10 years of follow-up 
among women diagnosed before 60 years. These survival 
improvements between periods of diagnoses could be 
due to better survival prospects for stage I and stage IV 
patients in 1995–2004 compared to 1985–1994. The most 
recent estimates of 10-year PBC among BC patients could 









Fig. 1  Long-term survival of breast cancer patients diagnosed in 
Girona and Tarragona before 85 years of age: a diagnosed ≤ 49 years 
during 1985–1994; b diagnosed  ≤  49  years during 1995–2004; c 
diagnosed  >  49  years during 1985–1994; d diagnosed  >  49  years 
during 1995–2004. *Since complete follow-up until December 31st, 
2014 for patients diagnosed between 1995–2004 was 10  years, fol-
low-up beyond 10  years was estimated using the cohorts diagnosed 
between 1995–1993 (11-year probabilities), 1995–1992 (12-year 
probabilities) and so on
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Breast Cancer (PBC): 1985-1994
Breast Cancer (PBC) : 1995-2004
Other Causes (POC) : 1985-1994
Other Causes (POC) : 1995-2004
PBC: Probability to die from Breast Cancer





Fig. 2  Comparison of the 10-year probabilities of death due to breast cancer and other causes between diagnostic periods 1985–1994 and 1995–
2004 by age groups: a ≤ 49 years; b (50–59) years; c (60–74) years; d (75–84) years. Shaded bands represent 95% confidence intervals
Table 2  Stage-distribution and mean age at diagnosis within stage between periods 1985–1994 and 1995–1994
%, Percentage with respect to the total in each time period
%*, Percentage with respect to N = 867 cases with stage confirmed during 1985–1994
%**, Percentage with respect to N = 5160 cases with stage confirmed during 1995–2004
Mean age mean age at diagnosis
Differences stage differences in the percentage of patients in Stage
95% CI 95% confidence interval of the difference
***95% confidence interval of the difference does not include 0
Stage 1985–1994 (N) (%) (%*) Mean age 1995–2004 (N) (%) (%**) Mean age Differences stage (differ-
ence) (95% CI)
I 230 (5.5) (26.5) 56.5 1783 (29.8) (34.6) 58.6 − 8.1*** (− 11.2; − 4.1)
II 392 (9.3) (45.2) 55.6 2300 (38.4) (44.6) 58.9 0.6 (− 3.1; 4.1)
III 130 (3.1) (15.0) 56.8 724 (12.1) (14.0) 59.6 1.0 (− 1.6; 3.5)
IV 115 (2.7) (13.3) 61.6 353 (5.9) (6.8) 63.4 6.46*** (3.9; 8.9)
Total with stage (N) 867 (20.6) (100) 56.8 5160 (86.2) (100) 59.2 –
Unknown stage 3344 (79.4) (–) 60.5 824 (13.8) (–) 63.9 –
Total 4211 (100) (–) 59.8 5984 (100) (–) 59.9 –
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to 46% in stage III, whereas PBC surpasses 70% in stage 
IV beyond 5 years of diagnoses.
Our approach has several strengths, in comparison with 
previous survival studies. First, we provide estimates of the 
crude probabilities of death due to BC and other causes using 
population-based cancer registry data from a Spanish cohort 
of BC patients, and, to date, this is the first study of this 
type carried out in Spain. These probabilities can be used 
as indicators to assess the improvement in overall OS and in 
quantifying the contribution of the disease to overall mortal-
ity [22]. Our approach makes a major difference with relative 
survival. Relative survival is used as population-based cancer 
survival indicator and as estimator for the net survival, but 
relative survival is not a survival probability measure [7, 21, 
22]. Second, we provided the most recent estimates of the 
10-year figures of these probabilities, where our study had 
86.2% completeness of this information in 1995–2004.
It is worth noting the strength limitation related with stag-
ing classification between diagnostic periods in our study, 
which was based on the 5th edition of the AJCC staging 
manual [20]. Since stage migration due to different classi-
fications could artifactually inflate cancer survival rates by 
shifting patients with better prognosis group into a worse 
prognosis group [24], we used unified staging classification 
to minimize this bias. However, there was a limitation related 
with survival outcomes in the classification of patients mak-
ing use of the AJCC fifth edition, since differences in sur-
vival among BC cases classified into stage IV could exist 
but not detected using this classification. The sixth edition 
of the AJCC has further amended the staging classification 
of patients with supraclavicular metastases at diagnosis to 
include them into the IIIC category [25], since evidence sug-
gests that these patients had similar outcomes than stage IIIB 
patients and even better outcomes than patients with visceral 
stage IV disease [26]. There are other limitations to be noted 
in the survival comparison between periods of diagnosis. 
Survival estimates beyond 10 year for patients diagnosed dur-
ing 1995–2004 were estimated using different subcohorts of 
patients during this time period. Second, availability of stage 
information in 1985–1994 was limited to N = 867 patients 
and probability estimates drawn from stage indicators in this 
time period could not be robust. These could also be biased, 
since patients with stage information in 1985–1994 had bet-
ter survival than patients without this information, and this 
may lead to an underestimation of the survival differences 
between time periods (Supplementary material: Table S3).
In our study, PBC substantially decreased beyond 1994, but 
significant excess mortality may remain beyond 10 years after 
diagnosis. This is in agreement with recent long-term survival 
studies [7, 18, 27]. Improvements in BC survival between 
1985–1994 and 1995–2004 in Spain could be attributable to 
changes due to BC screening, active in Girona and Tarragona 
since 1998–1999 [3], management and treatment [6]. In this line, 
we detected a 19% of risk of death reduction for BC patients diag-
nosed beyond 1995. Since BC screening is related to lead-time 
bias, it may increase the number of BC diagnosed at early stages 
(I) and decrease that number at advanced stages (IV). However, 
it is also difficult to quantify the contribution of BC screening in 
the mortality reduction without information about the diagnostic 
method, clinical or by screening, of tumor [28–30].
The introduction of the screening program may imply a 
reduction in advanced invasive cancers and then patient’s risk 
of mastectomy or chemotherapy for breast cancer, or side 
effects of these, may decrease [31]. In 1994, when most of 
the screening in Catalonia was opportunistic, rates of screen-
ing mammography switched from 27% (women aged 50–64) 
to 43% (women aged 40–49), whereas in 2004, 61.2% of 
the invited women participated in the national BC screening 
Table 3  All-cause mortality 
adjusted by age and stage using 
a Cox model
Period period of diagnosis, HR hazard ratio, 95% CI 95% confidence interval, Ref reference category
1985–1994 1995–2004 1985–2004
HR 95% CI HR 95% CI HR 95% CI
≤ 49 Ref. Ref. Ref.
(50–59) 1.17 1.01 1.35 1.06 0.91 1.06 1.12 1.01 1.24
(60–74) 1.52 1.34 1.72 1.54 1.36 1.54 1.54 1.41 1.68
(75–84) 3.22 2.82 3.68 3.06 2.7 3.06 3.17 2.9 3.48
Stage
 I Ref. Ref. Ref.
 II 1.72 1.22 2.43 2.22 1.93 2.22 2.09 1.84 2.37
 III 3.83 2.63 5.56 4.36 3.74 4.36 4.09 3.55 4.72
 IV 13.91 9.77 19.78 17.18 14.62 17.18 15.10 13.07 17.45
Missing 3.22 2.39 4.35 3.65 3.14 3.65 3.48 2.98 4.06
Period
 85–94 Ref
 95–04 0.81 0.71 0.91
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program and 75.7% either participated in that program or 
reported that they had received recent mammograms [30]. 
Overdiagnosis caused by the screening [30] may also be 
related with the improvement in survival prospects between 
periods. The influence of a potential stage migration (Will 
Rogers phenomenon) is a factor that could have influenced 
changes in survival by stages but not in the global survival 
[24]. On the other hand, the contribution in the reduction of 
BC mortality by treatment improvements is also difficult to 
quantify, since we found that hazard ratios by age and stage 
were of similar magnitude between diagnostic periods.
Our probability estimates are based in a competing’ risks 
modeling for which we attribute the excess risk of death of 
our patients to BC. This can be seen as the death probabilities 
that the cancer patients could “expect to have” in the hypo-
thetical scenario where cancer patients have the same death 
risks as the general population [7]. If we compare the 10-year 
PBC and POC estimates with the cause-specific proportion 
of deaths obtained making use of the death certificates (Sup-
plementary material: Table S4) considering all age groups, the 
difference between PBC and the proportion of deaths due to 
BC is 1.8% in both periods. In this line, the difference between 
POC and the proportion of deaths due to other causes is also 
small: − 1.9% in 1985–1994 and − 1.8% in 1995–2004. In our 
study, we associated these improvements with the decrease 
in the PBC between periods, since we did not find significant 
differences in the 10-year POC between time periods.
Future research will continue updating the follow-up up 
to 20 years for the most recent cohort. On the other hand, 
the data available did not allow us to investigate survival by 
molecular subtype of breast cancer (e.g., luminal A or B, tri-
ple negative, HER2), but evidence suggests that the prognostic 
value of molecular subtype persists when adjusting for age, 
stage and histological grade, and certain subtypes may metas-
tasized even when the tumor itself is localized [32]. However, 
this information will be retrieved for the cohort diagnosed 
beyond 2000, since hormone’s evaluation and HER2 status 
was not the standard of care in Spain before this year.
Conclusion
First, our analysis suggests that women diagnosed with BC 
have higher PBC than POC during the first 10 years after 
diagnosis. The reduction of 19% in risk of death beyond 
1995 was markedly due to the reduction in the PBC, since 
the POC did not change between periods. Access to BC 
screening and the improvements in treatment have had a 
positive impact on survival prospects of BC patients. To 
continue the improvement in long-term survival rates of BC 
patients, continued efforts should be pursued in (1) increas-
ing adherence to screening programmes with better quality 
and in (2) the introduction of therapeutic innovations.
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